Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Anti-Counterfeit Technology Policy Head Is Ex-CMS Staffer Rudolf

Executive Summary

FDA's development of a policy on technology-based anti-counterfeiting efforts will be overseen by Senior Advisor for Medical & Health Policy Paul Rudolf, MD
Advertisement

Related Content

FDA Economist Lutter To Head Policy & Planning Office After Hubbard Retires
FDA Economist Lutter To Head Policy & Planning Office After Hubbard Retires
FDA Counterfeit Drug Website “Icon” Considered For Education Campaign
FDA Counterfeit Drug Website “Icon” Considered For Education Campaign
FDA Counterfeit Report Seeks “Electronic Pedigree” To Aid Drug Tracking
FDA Counterfeit Task Force Continues Work On Wholesaler “Best Practices”
FDA Anti-Counterfeiting Public Meeting To Display Current Technology
FDA “Strategic Plan” Team Takes Shape: McClellan Names Senior Advisors
Advertisement
UsernamePublicRestriction

Register

PS042603

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel